A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19

Objective: Efficacy and safety of Itolizumab, an immunomodulatory mAb, in treating moderate-to-severe acute respiratory distress syndrome (ARDS) due to cytokine release in COVID-19 patients was evaluated in a multi-centric, open-label, two-arm, controlled, randomized, phase-2 study. Methods: Patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Suresh, De Souza, Rosemarie, Nadkar, Milind, Guleria, Randeep, Trikha, Anjan, Joshi, Shashank R., Loganathan, Subramanian, Vaidyanathan, Sivakumar, Marwah, Ashwani, Athalye, Sandeep N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040494/
https://www.ncbi.nlm.nih.gov/pubmed/33835886
http://dx.doi.org/10.1080/14712598.2021.1905794

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040494/
https://www.ncbi.nlm.nih.gov/pubmed/33835886
http://dx.doi.org/10.1080/14712598.2021.1905794

Ejemplares similares